Addus HomeCare
ADUS
113.27
+0.11
+0.10%
Addus HomeCare
US · ADUS
#2738 by market cap
Listed 1970
113.27
+0.11
+0.10%
Live - 5344 symbols - heartbeat 451s ago
· 2026-10-08 08:22
Pre-market
112.81
-0.41%
After-hours
113.27
0.00%
- Market cap
- 2.12B
- P/E (TTM)i
- 19.84
- P/Bi
- 1.84
- EPSi
- 5.22
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on ADUS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.47, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +23.21% YoY
Margins
- Gross margin
- 32.47%
- Operating margin
- 9.74%
- Net margin
- 6.74%
Key ratios & quality
- Enterprise valuei
- 2.17B
- PEG ratioi
- 0.72
- Altman Z-Scorei
- 5.47
PEG uses trailing P/E against the 3-year net income growth rate (27.73%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 516.65M | 648.79M | 764.78M | 864.50M | 951.12M | 1.06B | 1.15B | 1.42B |
| Gross profit | 136.80M | 179.24M | 226.24M | 269.85M | 299.74M | 339.88M | 375.02M | 461.87M |
| Selling & admin expenses | 105.34M | 133.91M | 169.68M | 189.42M | 216.94M | 234.79M | 258.80M | 306.85M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 22.83M | 34.75M | 44.51M | 65.94M | 68.74M | 90.96M | 102.69M | 138.62M |
| Pretax profit | 20.40M | 33.17M | 41.94M | 60.40M | 60.17M | 81.33M | 99.35M | 127.45M |
| Tax | 4.10M | 7.36M | 8.81M | 15.27M | 14.15M | 18.81M | 25.76M | 31.54M |
| Net profit | 16.43M | 25.24M | 33.13M | 45.13M | 46.03M | 62.52M | 73.60M | 95.91M |
| Basic EPS | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 |
| Diluted EPS | 1.33 | 1.77 | 2.08 | 2.81 | 2.84 | 3.83 | 4.23 | 5.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 337.71M | 349.44M | 362.30M | 373.08M | 363.61M | 377.42M |
| Gross profit | 107.68M | 113.88M | 116.72M | 123.61M | 115.87M | 121.56M |
| Selling & admin expenses | 73.22M | 77.08M | 79.37M | 77.18M | 77.77M | 78.49M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 30.51M | 32.89M | 32.94M | 42.28M | 34.07M | 38.94M |
| Pretax profit | 27.00M | 29.95M | 30.35M | 40.15M | 32.43M | 37.78M |
| Tax | 5.77M | 7.89M | 7.51M | 10.37M | 7.36M | 10.18M |
| Net profit | 21.23M | 22.05M | 22.85M | 29.78M | 25.07M | 27.61M |
| Basic EPS | 1 | 1 | 1 | 2 | 1 | 2 |
| Diluted EPS | 1.16 | 1.20 | 1.24 | 1.61 | 1.36 | 1.49 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 176.01M | 269.39M | 287.70M | 324.34M | 222.81M | 200.00M | 260.38M | 269.49M |
| Cash & ST investments | 70.41M | 111.71M | 145.08M | 168.90M | 79.96M | 64.79M | 98.91M | 81.62M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 348.09M | 636.75M | 892.58M | 947.59M | 937.99M | 1.02B | 1.41B | 1.44B |
| Total current liabilities | 61.50M | 87.53M | 143.90M | 117.69M | 131.15M | 145.12M | 155.87M | 149.49M |
| Short-term debt | 62.00K | 7.96M | 10.25M | 9.77M | 10.80M | 11.34M | 12.80M | 13.14M |
| Long-term debt | 17.22M | 59.16M | 193.90M | 220.91M | 131.77M | 124.13M | 218.44M | 120.96M |
| Total liabilities | 79,603,000.00 | 161,156,000.00 | 373,906,000.00 | 373,241,000.00 | 304,454,000.00 | 317,732,000.00 | 442,142,000.00 | 352,005,000.00 |
| Total equity | 268.49M | 475.59M | 518.68M | 574.34M | 633.54M | 706.69M | 970.49M | 1.09B |
| Retained earnings | 90.80M | 116.03M | 149.17M | 194.29M | 240.32M | 302.83M | 376.43M | 472.34M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 257.83M | 263.05M | 260.66M | 269.49M | 272.88M | 284.15M |
| Cash & ST investments | 96.95M | 91.18M | 101.92M | 81.62M | 103.07M | 99.57M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.41B | 1.41B | 1.42B | 1.44B | 1.44B | 1.46B |
| Total current liabilities | 147.94M | 151.38M | 156.80M | 149.49M | 149.48M | 168.15M |
| Short-term debt | 12.65M | 12.97M | 13.03M | 13.14M | 13.14M | 13.06M |
| Long-term debt | 198.74M | 169.06M | 150.64M | 120.96M | 91.27M | 61.60M |
| Total liabilities | 412,201,000.00 | 387,077,000.00 | 372,964,000.00 | 352,005,000.00 | 319,540,000.00 | 308,329,000.00 |
| Total equity | 995.38M | 1.02B | 1.05B | 1.09B | 1.12B | 1.15B |
| Retained earnings | 397.66M | 419.71M | 442.56M | 472.34M | 497.41M | 525.02M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 33.20M | 12.02M | 109.41M | 39.49M | 105.11M | 112.25M | 116.43M | 111.51M |
| Depreciation & amortization | 8.64M | 10.57M | 12.05M | 14.49M | 14.06M | 14.13M | 13.53M | 16.41M |
| Free cash flow | 27.85M | 7.40M | 102.58M | 34.84M | 96.81M | 102.79M | 110.38M | 103.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 76.62M | 172.95M | 0 | -- | 0 | 0 | 175.60M | 0 |
| Ending cash balance | 70.41M | 111.71M | 145.08M | 168.90M | 79.96M | 64.79M | 98.91M | 81.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 18.95M | 22.53M | 51.27M | 18.76M | 52.37M | 40.01M |
| Depreciation & amortization | 3.94M | 3.91M | 4.41M | 4.15M | 4.03M | 4.13M |
| Free cash flow | 17.07M | 21.28M | 49.35M | 16.10M | 50.65M | 38.67M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 96.95M | 91.18M | 101.92M | 81.62M | 103.07M | 99.57M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.77 | 6.72 | 6.66 | 8.26 | 7.62 | 9.33 | 8.78 | 9.33 |
| ROA %i | 5.62 | 5.09 | 4.33 | 4.90 | 4.88 | 6.37 | 6.04 | 6.73 |
| ROIC %i | 7.61 | 6.23 | 5.35 | 6.17 | 6.38 | 8.26 | 7.16 | 8.34 |
| 5-year avg ROE %i | 8.28 | 7.61 | 7.22 | 7.25 | 7.34 | 7.73 | 8.13 | 8.66 |
| EBIT margin %i | 5.19 | 5.59 | 5.90 | 7.66 | 7.26 | 8.73 | 9.27 | 9.92 |
| FCF / sales %i | 5.38 | 1.14 | 13.41 | 4.03 | 10.18 | 9.71 | 9.56 | 7.30 |
| Current ratioi | 2.86 | 3.08 | 2.00 | 2.76 | 1.70 | 1.38 | 1.67 | 1.80 |
| Quick ratioi | 2.78 | 3.03 | 1.94 | 2.68 | 1.57 | 1.25 | 1.50 | 1.63 |
| Debt / assetsi | 4.97 | 12.79 | 26.85 | 27.81 | 18.98 | 17.10 | 19.33 | 11.92 |
| LT debt / equityi | 6.41 | 15.45 | 44.23 | 44.18 | 26.40 | 23.18 | 26.82 | 14.58 |
| Interest coveragei | 5.36 | 11.68 | 14.15 | 11.40 | 7.76 | 8.32 | 13.85 | 10.36 |
| Revenue CAGR (3Y) %i | 15.33 | 17.40 | 21.54 | 18.72 | 13.60 | 11.45 | 10.13 | 14.36 |
| Net income CAGR (3Y) %i | 12.24 | 27.56 | 40.47 | 40.04 | 22.18 | 23.57 | 17.71 | 27.73 |
| FCF CAGR (3Y) %i | 151.69 | -- | 27.79 | 7.75 | 135.65 | 0.07 | 46.87 | 2.35 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 9.18 | 8.54 | 8.58 | 9.33 | 9.45 | 9.71 |
| ROA %i | 6.52 | 6.57 | 6.65 | 6.73 | 7.02 | 7.35 |
| ROIC %i | 7.77 | 7.89 | 8.27 | 8.34 | 8.53 | 8.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.41 | 9.49 | 9.41 | 9.92 | 9.98 | 10.20 |
| FCF / sales %i | 7.44 | 7.35 | 7.16 | 7.30 | 9.48 | 10.48 |
| Current ratioi | 1.74 | 1.74 | 1.66 | 1.80 | 1.83 | 1.69 |
| Quick ratioi | 1.61 | 1.55 | 1.52 | 1.63 | 1.68 | 1.47 |
| Debt / assetsi | 17.82 | 15.77 | 14.23 | 11.92 | 9.66 | 7.47 |
| LT debt / equityi | 23.93 | 20.48 | 18.04 | 14.58 | 11.25 | 8.34 |
| Interest coveragei | 12.68 | 11.62 | 9.62 | 10.36 | 12.31 | 15.15 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Personal Care is the largest reported line at 78.43% of revenue, across 3 reported segments.
- The next-largest line, Hospice, is a distant second at 17.02% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Personal Care78.43%
Hospice17.02%
Home Health4.55%
Quote time 2026-10-08 08:22:23 · For reference only, not investment advice and not tailored to your situation.